CTLA4 and melanoma: Although we only profiled two such cases and larger cohorts are needed, a low point mutation burden relative to human sun-exposed melanoma has potential bearing on expected responses to immunotherapy such as anti-CTLA4 and anti-PD1 checkpoint blockade.